|
J&J Discloses New Investigations, Risperdal Agreement
Johnson & Johnson (J&J) is facing two new federal investigations into its marketing practices for a drug and a device, just as it is hammering out a settlement over off-label allegations for its antipsychotic Risperdal.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives